Robert Rifkin
Cardiovascular Disease · Saint Louis, MONPI 1417975053
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 98.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $97,422 and has fallen 99.7% since, to $310 in 2025. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $1431.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$142K
- Amgen$974
- Lundbeck LLC$330
- Almatica Pharma LLC$136
- Livanova USA, Inc.$130
- Dentsply Sirona Inc$100
- plus $521 from 12 others
Across 2 payments — averaging $67,506 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$134K
- Boehringer Ingelheim International GmbH$612
What the payments were for
- Consulting fees$64,69045%
- Speaking & faculty fees$78,62454%
- Food & beverage$1,1171%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 46 | $142,340 |
| Amgen | 1 | $974 |
| Lundbeck LLC | 14 | $330 |
| Almatica Pharma LLC | 9 | $136 |
| Livanova USA, Inc. | 5 | $130 |
| Dentsply Sirona Inc | 1 | $100 |
| Neuropace, Inc. | 1 | $95 |
| Ironshore Pharmaceuticals Inc. | 4 | $89 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Bausch Health US, LLC | 3 | $63 |
| Neos Therapeutics, LP | 4 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Shire North American Group Inc | 2 | $28 |
| Tris Pharma Inc | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Novo Nordisk | 1 | $12 |
| Alkermes, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEREC$100
How this compares
$144,531 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Louis
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- Osler Jay GuzonSaint Louis$211K
- Mohammad TahirSaint Louis$173K
- Martin SchwarzeSaint Louis$113K
- Joshua MitchellSaint Louis$103K
- Zainab MahmoudSaint Louis$100K
- Nizar AssiSaint Louis$81K
- Mustafa HusainiSaint Louis$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.